Loading...
•
Sep 30, 2024
Elanco Q3 2024 Earnings Report
Elanco's Q3 2024 financial results were reported, with revenue of $1,030 million and organic constant currency growth of 1%.
Key Takeaways
Elanco Animal Health reported its Q3 2024 financial results, achieving revenue of $1,030 million with 1% organic constant currency growth. The company received U.S. FDA approval for Zenrelia™ and Credelio Quattro™, and tightened its full-year 2024 financial guidance.
Revenue reached $1,030 million, with organic constant currency growth of 1%.
Reported EPS was $0.73, and Adjusted EPS was $0.13.
U.S. FDA approved Zenrelia™ and Credelio Quattro™.
Full-year 2024 revenue guidance tightened to $4,420 to $4,450 million, with 3% organic constant currency growth.
Elanco
Elanco
Elanco Revenue by Segment
Revenue by Segment
Pet Health Revenue
CapyFin.comFarm Animal Revenue
CapyFin.comCattle Revenue
CapyFin.comPoultry Revenue
CapyFin.comSwine Revenue
CapyFin.comAqua Revenue
CapyFin.com Forward Guidance
Elanco is tightening financial guidance for the full year 2024 and providing guidance for the fourth quarter of 2024.
Positive Outlook
- Revenue between $1.00 billion and $1.03 billion is anticipated for Q4 2024.
- Organic constant currency revenue growth of 1% to 4% is expected in Q4 2024.
- Full year 2024 revenue is projected to be between $4,420 to $4,450 million.
- Full year 2024 organic constant currency growth is expected to be 3%.
- Innovation sales contribution is expected between $420 million to $450 million for the full year.
Challenges Ahead
- Reported net loss is expected to be between $(59) million and $(32) million for Q4 2024.
- The impact of foreign exchange rates on revenue is expected to be a headwind of approximately $5 million in Q4 2024.
- The impact of foreign exchange rates on revenue is now expected to be a headwind of approximately $25 million for full year 2024.
- Gross margin headwinds from product mix and manufacturing performance are expected.
- Underlying adjusted EBITDA growth in 2025 is impacted by an anticipated $25 million to $35 million year-over-year headwind from the court-supervised insolvency of a key U.K-based contract manufacturing partner.
Revenue & Expenses
Visualization of income flow from segment revenue to net income